Heparin-Natrium Multi Braun (Heparin Sodium)

Heparin‑Natrium Multi Braun is indicated for clinical situations where inhibition of clot formation is required.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of clot formation in patients undergoing major surgery or orthopedic procedures.
• Anticoagulation during extracorporeal circulation such as hemodialysis, cardiopulmonary bypass, or plasma exchange.
• Management of acute coronary syndromes when combined with other antithrombotic agents.
• Prevention of catheter‑related thrombosis in central venous access devices.

Adverse reactions to Heparin‑Natrium Multi Braun reflect its anticoagulant activity and may involve bleeding or immune‑mediated events.

Common

• Minor bleeding at injection sites or from mucous membranes.
• Bruising or hematoma formation.
• Localized pain or erythema at the injection area.
• Transient elevation of liver enzymes.
• Nausea or mild headache.

Serious

• Major hemorrhage, including gastrointestinal or intracranial bleeding.
• Heparin‑induced thrombocytopenia (HIT) with a risk of new thrombosis.
• Spontaneous adrenal or retroperitoneal hemorrhage.
• Severe allergic reactions such as anaphylaxis.
• Disseminated intravascular coagulation (rare).

Use of Heparin‑Natrium Multi Braun requires careful assessment of bleeding risk and monitoring of coagulation parameters.

• Assess patient history for active bleeding, recent surgery, or trauma before initiating therapy.
• Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range.
• Use caution in patients with renal or hepatic impairment, adjusting dose as needed.
• Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products.
• Consider alternative anticoagulation during pregnancy, as safety data are limited.
• Discontinue or reduce dose prior to invasive procedures to minimize bleeding.
• Educate patients about signs of bleeding and thrombocytopenia.

Heparin‑Natrium Multi Braun can interact with other agents that affect hemostasis or drug metabolism.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without specialist guidance.
• Antiplatelet drugs such as aspirin, clopidogrel, or ticagrelor.
• Thrombolytic agents (e.g., alteplase, streptokinase).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• ACE inhibitors and angiotensin receptor blockers, which may potentiate hypotension during rapid infusion.
• Corticosteroids, which can increase gastrointestinal bleeding risk.
• Certain antibiotics (e.g., vancomycin, aminoglycosides) that may affect platelet function.
• Lipid‑lowering agents such as statins, which have rare reports of enhanced anticoagulant effect.